Month: April 2022

news_6

BeiGene Announces European Medicines Agency Acceptance of Marketing Authorization Applications for Tislelizumab for the Treatment of Patients with ESCC and NSCLC

First European Submissions for BeiGene’s Anti PD-1 antibody Licensed to Novartis for North America, Europe and Japan BASEL, Switzerland &...